Table 1.
Characteristics | All No. (%) |
FIB-4 Score | p a | |
---|---|---|---|---|
≤3.25 No. (%) |
>3.25 No. (%) |
|||
Overall | 343 (100.0) | 155 (45.2) | 188 (54.8) | |
Age, years | ||||
Median (IQR) | 35.4 (31.3–39.3) | 34.6 (30.2–38.6) | 36.0 (31.8–40.3) | 0.029 |
Sex | ||||
Male | 336 (98.0) | 151 (97.4) | 185 (98.4) | 0.796 |
Female | 7 (2.0) | 4 (2.6) | 3 (1.6) | |
Marital status | 0.210 | |||
Unmarried | 130 (37.9) | 61 (39.4) | 69 (36.7) | |
Married | 178 (51.9) | 74 (47.7) | 104 (55.3) | |
Divorced/widowed | 35 (10.2) | 20 (12.9) | 15 (8.0) | |
Ethnicity | 0.151 | |||
Han | 157 (45.8) | 62 (40.0) | 95 (50.5) | |
Dai | 112 (32.6) | 60 (38.7) | 52 (27.7) | |
Jingpo | 62 (18.1) | 28 (18.1) | 34 (18.1) | |
Others | 12 (3.5) | 5 (3.2) | 7 (3.7) | |
HIV transmission route | 0.185 | |||
IDU | 314 (91.5) | 140 (90.3) | 174 (92.6) | |
Others | 29 (8.5) | 15 (9.7) | 14 (7.4) | |
Glucose level (IQR) | 5.20 (4.32–6.00) | 5.29 (4.31–6.03) | 5.16 (4.37–5.89) | 0.489 |
Baseline CD4, cells/ul | 0.618 | |||
<200 | 98 (29.0) | 40 (26.3) | 58 (31.2) | |
200–349 | 139 (41.1) | 65 (42.8) | 74 (39.8) | |
≥350 | 101 (29.9) | 47 (30.9) | 54 (29.0) | |
Current CD4, cells/ul | 0.511 | |||
<200 | 21 (6.1) | 7 (4.5) | 14 (7.4) | |
200–349 | 52 (15.2) | 23 (14.8) | 29 (15.4) | |
≥350 | 270 (78.7) | 125 (80.6) | 145 (77.1) | |
HCV RNA | 0.234 | |||
Undetectable | 105 (30.6) | 53 (34.2) | 52 (27.7) | |
Detectable | 238 (69.4) | 102 (65.8) | 136 (72.3) | |
HIV RNA | 0.053 | |||
Undetectable | 264 (89.3) | 126 (88.1) | 138 (79.3) | |
Detectable | 53 (10.7) | 17 (11.9) | 36 (20.7) | |
Years on cART | 5.7 (4.2–8.4) | 5.1 (3.9–7.6) | 6.1 (4.4–8.9) | 0.001 |
HBsAg positive | 0.685 | |||
Yes | 30 (8.7) | 12 (7.7) | 18 (9.6) | |
No | 313 (91.3) | 143 (92.3) | 170 (90.4) | |
cART regimen, % | 0.012 | |||
NVP (vs. EFV/RTV) | 136 (39.7) | 52 (33.5) | 84 (44.7) | |
TDF (vs. AZT/d4T/DDI) | 147 (42.9) | 80 (51.6) | 67 (35.6) | |
Others | 60 (17.4) | 23 (14.8) | 37 (19.7) | |
HCV genotype | 0.182 | |||
1 | 46 (16.0) | 23 (18.1) | 23 (14.4) | |
3 | 135 (47.0) | 52 (40.9) | 83 (51.9) | |
6 | 106 (37.0) | 52 (40.9) | 54 (33.8) |
IDU, injection drug use; NVP, nevirapine; EFV, efavirenz; RTV, Ritonavir; TDF, tenofovir; AZT, zidovudine; DDI, di-deoxyinosine; d4T, stavudine; a Chi-square tests or the Mann–Whitney U test were performed wherever appropriate; bold signifies statistical significance as p < 0.05.